MEN1
Menin
As of the edition of 20 October 2026, MEN1 (menin, UniProt O00255) has 4 drugs tested at it and 6 companies on the list, 0 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- O00255
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 69
- Disease areas
- Cancer; Blood and lymph; Immune system; Hormones; Nutrition and metabolism; Digestive system; Heart and blood vessels; Infections
- Registered trials of its drugs
- 55
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 2 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Revumenib | Marketed | Phase 3 | Ends 2037 |
| Ziftomenib | Marketed | Phase 3 | Ends 2044 |
| Icovamenib | Active | Phase 2 | none listed |
| Bleximenib | Active | Phase 3 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 2 |
| Engaged | 4 |
| Total on the list | 6 |
| Company | Route |
|---|---|
| Syndax Pharmaceuticals | Route B |
| Kura Oncology | Route B |
The other 4 companies at MEN1
In the product6 companies in all; 4 are not named here, and no score is.
See the 6 companies at MEN1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.